JP2009149648A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009149648A5 JP2009149648A5 JP2008325914A JP2008325914A JP2009149648A5 JP 2009149648 A5 JP2009149648 A5 JP 2009149648A5 JP 2008325914 A JP2008325914 A JP 2008325914A JP 2008325914 A JP2008325914 A JP 2008325914A JP 2009149648 A5 JP2009149648 A5 JP 2009149648A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- aminomethyl
- carbonyl
- isobutanoyloxyethoxy
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 239000013078 crystal Substances 0.000 claims 17
- TZDUHAJSIBHXDL-UHFFFAOYSA-N gabapentin enacarbil Chemical compound CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1 TZDUHAJSIBHXDL-UHFFFAOYSA-N 0.000 claims 17
- 238000010521 absorption reaction Methods 0.000 claims 11
- 238000000634 powder X-ray diffraction Methods 0.000 claims 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- LJOODBDWMQKMFB-UHFFFAOYSA-N cyclohexylacetic acid Chemical compound OC(=O)CC1CCCCC1 LJOODBDWMQKMFB-UHFFFAOYSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010006002 Bone pain Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 206010061296 Motor dysfunction Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 238000000113 differential scanning calorimetry Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- -1 α-isobutanoyloxyethoxy Chemical group 0.000 claims 1
- 150000003953 γ-lactams Chemical class 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51128703P | 2003-10-14 | 2003-10-14 | |
| US60/511,287 | 2003-10-14 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006535673A Division JP4308263B2 (ja) | 2003-10-14 | 2004-10-14 | γ−アミノ酪酸アナログの結晶形 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009149648A JP2009149648A (ja) | 2009-07-09 |
| JP2009149648A5 true JP2009149648A5 (enExample) | 2009-11-12 |
| JP4913796B2 JP4913796B2 (ja) | 2012-04-11 |
Family
ID=34465215
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006535673A Expired - Lifetime JP4308263B2 (ja) | 2003-10-14 | 2004-10-14 | γ−アミノ酪酸アナログの結晶形 |
| JP2008325914A Expired - Lifetime JP4913796B2 (ja) | 2003-10-14 | 2008-12-22 | γ−アミノ酪酸アナログの結晶形 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006535673A Expired - Lifetime JP4308263B2 (ja) | 2003-10-14 | 2004-10-14 | γ−アミノ酪酸アナログの結晶形 |
Country Status (22)
| Country | Link |
|---|---|
| US (10) | US8026279B2 (enExample) |
| EP (1) | EP1677767B1 (enExample) |
| JP (2) | JP4308263B2 (enExample) |
| KR (1) | KR101096480B1 (enExample) |
| CN (1) | CN1867322B (enExample) |
| AT (1) | ATE516801T1 (enExample) |
| AU (1) | AU2004282192B2 (enExample) |
| BR (1) | BRPI0415288B8 (enExample) |
| CA (1) | CA2541752C (enExample) |
| DK (1) | DK1677767T3 (enExample) |
| ES (1) | ES2368916T3 (enExample) |
| IL (2) | IL174600A (enExample) |
| MX (1) | MXPA06004088A (enExample) |
| NO (1) | NO338275B1 (enExample) |
| NZ (1) | NZ546381A (enExample) |
| PL (1) | PL1677767T3 (enExample) |
| PT (1) | PT1677767E (enExample) |
| RU (1) | RU2412162C2 (enExample) |
| SG (1) | SG147437A1 (enExample) |
| SI (1) | SI1677767T1 (enExample) |
| WO (1) | WO2005037784A2 (enExample) |
| ZA (1) | ZA200602722B (enExample) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US8048917B2 (en) * | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7025745B2 (en) * | 2002-10-07 | 2006-04-11 | Advanced Cardiovascular Systems, Inc. | Method of making a catheter balloon using a tapered mandrel |
| CA2537837A1 (en) * | 2003-09-11 | 2005-03-24 | Xenoport, Inc. | Treating and/or preventing urinary incontinence using prodrugs of gaba analogs |
| CA2538802C (en) * | 2003-09-17 | 2015-01-27 | Xenoport, Inc. | Treating or preventing restless legs syndrome using prodrugs of gaba analogs |
| CA2541752C (en) | 2003-10-14 | 2012-01-03 | Xenoport, Inc. | Crystalline form of gamma-aminobutyric acid analog |
| US20050209319A1 (en) * | 2004-03-18 | 2005-09-22 | Xenoport, Inc. | Treatment of local pain |
| EP1811986B1 (en) | 2004-11-04 | 2014-03-26 | XenoPort, Inc. | Gabapentin prodrug sustained release oral dosage forms |
| EP1919859B1 (en) * | 2005-06-20 | 2010-06-02 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs of tranexamic acid and use |
| CA2672044A1 (en) * | 2006-12-08 | 2008-06-19 | Xenoport, Inc. | Use of prodrugs of gaba analogs for treating diseases |
| CA2674610C (en) * | 2007-01-11 | 2013-06-18 | Xenoport, Inc. | Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment |
| US20090118365A1 (en) * | 2007-11-06 | 2009-05-07 | Xenoport, Inc | Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain |
| WO2010008886A2 (en) * | 2008-06-24 | 2010-01-21 | Teva Pharmaceutical Industries Ltd. | Processes for preparing prodrugs of gabapentin and intermediates thereof |
| KR20110028320A (ko) * | 2008-07-02 | 2011-03-17 | 테바 파마슈티컬 인더스트리즈 리미티드 | 가바펜틴 에나카르빌 염 및 이의 제조 방법 |
| WO2010017504A1 (en) * | 2008-08-07 | 2010-02-11 | Xenoport, Inc. | Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs |
| WO2010017498A1 (en) | 2008-08-07 | 2010-02-11 | Xenoport, Inc. | Methods of synthesizing n-hydroxysuccinimidyl carbonates |
| WO2010063002A2 (en) | 2008-11-26 | 2010-06-03 | Teva Pharmaceutical Industries Ltd. | Processes for the preparation and purification of gabapentin enacarbil |
| WO2010075520A1 (en) * | 2008-12-23 | 2010-07-01 | Teva Pharmaceutical Industries Ltd. | Preparation of gabapentin enacarbil intermediate |
| US20110303570A1 (en) * | 2009-03-02 | 2011-12-15 | Astellas Pharma Inc. | Package of solid pharmaceutical preparation |
| US10071068B2 (en) * | 2009-03-03 | 2018-09-11 | Xenoport, Inc. | Sustained release oral dosage forms of an R-baclofen prodrug |
| CN102341098A (zh) * | 2009-03-06 | 2012-02-01 | 什诺波特有限公司 | 具有高负荷的加巴喷丁前药的口服剂型 |
| WO2011028234A1 (en) * | 2009-09-04 | 2011-03-10 | Xenoport, Inc. | Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid |
| WO2011091164A1 (en) | 2010-01-22 | 2011-07-28 | Xenoport, Inc. | Oral dosage forms having a high loading of a tranexamic acid prodrug |
| US20110263701A1 (en) * | 2010-04-21 | 2011-10-27 | Sigal Blau | Gabapentin enacarbil compositions |
| WO2013008182A1 (en) * | 2011-07-10 | 2013-01-17 | Mahesh Kandula | Prodrugs of gaba analogs |
| US9303038B2 (en) | 2011-09-06 | 2016-04-05 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological diseases |
| WO2013168019A1 (en) * | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neuropathic pain |
| JP2015522531A (ja) | 2012-05-07 | 2015-08-06 | セリックスビオ プライヴェート リミテッド | 神経筋疾患及び神経変性疾患の治療のための組成物及び方法 |
| WO2013167990A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of depression |
| US9738631B2 (en) | 2012-05-07 | 2017-08-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
| US9266823B2 (en) | 2012-05-08 | 2016-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of parkinson's disease |
| US9522884B2 (en) | 2012-05-08 | 2016-12-20 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic disorders |
| US9309233B2 (en) | 2012-05-08 | 2016-04-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of blood clotting disorders |
| US9403826B2 (en) | 2012-05-08 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory disorders |
| US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
| SG11201407318UA (en) | 2012-05-10 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of metabolic syndrome |
| US9315461B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
| WO2013168002A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological conditions |
| US9321775B2 (en) | 2012-05-10 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of moderate to severe pain |
| WO2013168004A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of fibromyalgia pain |
| US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
| US9499526B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
| WO2013168015A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of asthma and allergy |
| US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
| WO2013168000A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of severe pain |
| WO2013167997A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
| WO2013168011A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of chronic pain |
| US9242939B2 (en) | 2012-05-10 | 2016-01-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
| US9498461B2 (en) | 2012-05-23 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
| AU2013264820A1 (en) | 2012-05-23 | 2014-11-27 | Cellixbio Private Limited | Compositions and methods for treatment of mucositis |
| WO2013175376A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of local pain |
| WO2013175347A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
| WO2013175344A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
| AU2013264896A1 (en) | 2012-05-23 | 2014-11-27 | Cellixbio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| WO2014020480A2 (en) | 2012-08-03 | 2014-02-06 | Mahesh Kandula | Compositions and methods for the treatment migraine and neurologic diseases |
| US9624168B2 (en) | 2012-09-06 | 2017-04-18 | Cellix Bio Private Limited | Compositions and methods for the treatment inflammation and lipid disorders |
| CA2873029A1 (en) | 2012-09-08 | 2014-03-13 | Cellixbio Private Limited | Compositions and methods for the treatment of inflammation and lipid disorders |
| EP2961730A2 (en) | 2013-02-26 | 2016-01-06 | XenoPort, Inc. | Method of making 1-(acyloxy)-alkyl carbamate compounds |
| US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
| SG11201509782TA (en) | 2013-06-04 | 2015-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of diabetes and pre-diabetes |
| US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
| EP3240779B1 (en) | 2014-09-26 | 2020-10-28 | Cellixbio Private Limited | Compositions and methods for the treatment of epilepsy and neurological disorders |
| ES2799309T3 (es) | 2014-09-29 | 2020-12-16 | Cellix Bio Private Ltd | Compuestos y composiciones para el tratamiento de esclerosis múltiple |
| CA2965449C (en) | 2014-10-27 | 2020-11-10 | Cellix Bio Private Limited | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
| US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
| US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
| US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
| US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
| US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
| CN107207411A (zh) | 2014-12-01 | 2017-09-26 | 塞尔利克斯生物私人有限公司 | 用于治疗多发性硬化的组合物和方法 |
| US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
| ES2905771T3 (es) | 2015-01-06 | 2022-04-12 | Cellix Bio Private Ltd | Composiciones y procedimientos para el tratamiento de la inflamación y del dolor |
| RU2739192C1 (ru) * | 2020-06-18 | 2020-12-21 | федеральное государственное бюджетное образовательное учреждение высшего образования «Омский государственный медицинский университет» Министерства здравоохранения Российской Федерации (ФГБОУ ВО ОмГМУ Минздрава России) | Способ лечения абстинентного синдрома, с целью превенции развития психоза, у лиц с зависимостью от синтетических агонистов рецепторов гамма-аминомасляной кислоты: бутиролактона, 1,4-бутандиола |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| DE2460891C2 (de) | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US4087544A (en) | 1974-12-21 | 1978-05-02 | Warner-Lambert Company | Treatment of cranial dysfunctions using novel cyclic amino acids |
| JPS62258337A (ja) | 1986-04-30 | 1987-11-10 | Kuraray Co Ltd | ４−ヒドロキシ−２，４，６−トリメチル−２，５−シクロヘキサジエン−１−オンの精製法 |
| DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
| DE3928183A1 (de) | 1989-08-25 | 1991-02-28 | Goedecke Ag | Lactamfreie cyclische aminosaeuren |
| US5084169A (en) | 1989-09-19 | 1992-01-28 | The University Of Colorado Foundation, Inc. | Stationary magnetically stabilized fluidized bed for protein separation and purification |
| US5084479A (en) | 1990-01-02 | 1992-01-28 | Warner-Lambert Company | Novel methods for treating neurodegenerative diseases |
| US6197819B1 (en) | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
| WO1992009560A1 (en) | 1990-11-27 | 1992-06-11 | Northwestern University | Gaba and l-glutamic acid analogs for antiseizure treatment |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| DK0641330T3 (da) | 1992-05-20 | 2001-12-03 | Univ Northwestern | Gaba- og L-glutaminsyreanaloger til antikrampeanfaldsbehandling |
| DE69712877T2 (de) | 1996-02-07 | 2002-11-14 | Warner-Lambert Co., Morris Plains | Zyklischaminosäure als pharmazeutische mittel |
| DK0888286T3 (da) | 1996-03-14 | 2002-02-18 | Warner Lambert Co | Nye substituerede cykliske aminosyrer som farmaceutiske midler |
| EA001214B1 (ru) | 1996-03-14 | 2000-12-25 | Варнер-Ламберт Компани | Новые мостиковые циклические аминокислоты как фармацевтически применимые вещества |
| EP0934061B3 (en) | 1996-07-24 | 2015-01-21 | Warner-Lambert Company LLC | Isobutylgaba and its derivatives for the treatment of pain |
| SE9603408D0 (sv) * | 1996-09-18 | 1996-09-18 | Astra Ab | Medical use |
| NZ334898A (en) | 1996-10-23 | 2000-09-29 | Warner Lambert Co | Substituted gamma aminobutyric acids as pharamceutical agents |
| AU8668598A (en) | 1997-08-20 | 1999-03-08 | University Of Oklahoma, The | Gaba analogs to prevent and treat gastrointestinal damage |
| ATE323067T1 (de) | 1997-10-27 | 2006-04-15 | Warner Lambert Co | Zyklische aminosäuren und deren derivate als arzneimittel |
| NZ503963A (en) | 1997-12-16 | 2002-09-27 | Warner Lambert Co | 1-substituted-1-aminomethyl-cycloalkane derivatives, or gabapentin analogues, preparation and use in the treatment of neurological disorders |
| CN1279667A (zh) | 1997-12-16 | 2001-01-10 | 沃尼尔·朗伯公司 | 4(3)取代－4(3)－氨基甲基－(硫代)吡喃(噻喃)或－哌啶衍生物(=加巴喷丁类似物)、其制备及其在治疗神经病方面的用途 |
| WO1999031074A2 (en) | 1997-12-16 | 1999-06-24 | Warner-Lambert Company | ((cyclo)alkyl substituted)-.gamma.-aminobutyric acid derivatives (=gaba analogues), their preparation and their use in the treatment of neurological disorders |
| US6605610B1 (en) | 1997-12-31 | 2003-08-12 | Pfizer Inc | Aryl fused azapolycyclic compounds |
| CA2309354A1 (en) | 1998-01-23 | 1999-07-29 | Leslie Magnus-Miller | Gabapentin and its derivatives for the treatment of muscular and skeletal pain |
| JP2002516312A (ja) | 1998-05-26 | 2002-06-04 | ワーナー−ランバート・カンパニー | カルシウムチャンネルのα２δサブユニットに対する親和性を有する立体配座的に制約されたアミノ酸化合物 |
| AUPP396998A0 (en) | 1998-06-09 | 1998-07-02 | University Of Melbourne, The | A method for increasing the permeability of wood |
| WO2000023067A1 (en) | 1998-10-16 | 2000-04-27 | Warner-Lambert Company | Method for the treatment of mania and bipolar disorder |
| WO2000031020A1 (en) | 1998-11-25 | 2000-06-02 | Warner-Lambert Company | Improved gamma amino butyric acid analogs |
| EP1031350A1 (en) | 1999-02-23 | 2000-08-30 | Warner-Lambert Company | Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain |
| CA2362026A1 (en) | 1999-04-08 | 2000-10-19 | Warner-Lambert Company | Method for the treatment of incontinence |
| US6992109B1 (en) | 1999-04-08 | 2006-01-31 | Segal Catherine A | Method for the treatment of incontinence |
| PT1202725E (pt) | 1999-07-22 | 2007-07-11 | Universuty Of Rochester | Método para tratar sintomas de alteração hormonal, incluindo afrontamentos. |
| GB2362646A (en) | 2000-05-26 | 2001-11-28 | Warner Lambert Co | Cyclic amino acid derivatives useful as pharmaceutical agents |
| NZ522480A (en) | 2000-06-26 | 2005-06-24 | Warner Lambert Co | Gabapentin analogues for sleep disorders |
| GB2365425A (en) | 2000-08-01 | 2002-02-20 | Parke Davis & Co Ltd | Alkyl amino acid derivatives useful as pharmaceutical agents |
| WO2002028881A1 (en) | 2000-10-06 | 2002-04-11 | Xenoport, Inc. | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration |
| WO2002044324A2 (en) | 2000-10-06 | 2002-06-06 | Xenoport, Inc. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
| AU2002230398A1 (en) | 2000-10-06 | 2002-04-29 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
| GB2368579A (en) | 2000-10-31 | 2002-05-08 | Parke Davis & Co Ltd | Azole pharmaceutical agents |
| AU2002239257A1 (en) | 2000-11-17 | 2002-06-03 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| JP2002346303A (ja) | 2001-05-28 | 2002-12-03 | Mitsubishi Chemicals Corp | 晶析方法 |
| JP2002355501A (ja) | 2001-05-30 | 2002-12-10 | Sumitomo Chem Co Ltd | 滴下晶析方法 |
| AU2002310409C1 (en) | 2001-06-11 | 2008-04-17 | Xenoport, Inc. | Orally administered dosage forms of GABA analog prodrugs having reduced toxicity |
| US7232924B2 (en) * | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
| US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US6927036B2 (en) | 2002-02-19 | 2005-08-09 | Xero Port, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
| MXPA05010515A (es) | 2003-03-31 | 2006-03-10 | Xenoport Inc | Tratamiento o prevencion de sofocos calientes utilizando profarmacos de analogos de gaba. |
| US6816787B2 (en) | 2003-03-31 | 2004-11-09 | Schlumberger Technology Corporation | Generating and displaying a virtual core and a virtual plug associated with a selected piece of the virtual core |
| WO2005010011A2 (en) | 2003-07-15 | 2005-02-03 | Xenoport, Inc. | Methods of synthesis of acyloxyalkyl compounds |
| CA2537837A1 (en) | 2003-09-11 | 2005-03-24 | Xenoport, Inc. | Treating and/or preventing urinary incontinence using prodrugs of gaba analogs |
| CA2538802C (en) | 2003-09-17 | 2015-01-27 | Xenoport, Inc. | Treating or preventing restless legs syndrome using prodrugs of gaba analogs |
| CA2541752C (en) * | 2003-10-14 | 2012-01-03 | Xenoport, Inc. | Crystalline form of gamma-aminobutyric acid analog |
| CA2551859C (en) | 2003-12-30 | 2011-10-04 | Xenoport, Inc. | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof |
| US20050209319A1 (en) | 2004-03-18 | 2005-09-22 | Xenoport, Inc. | Treatment of local pain |
| EP1811986B1 (en) | 2004-11-04 | 2014-03-26 | XenoPort, Inc. | Gabapentin prodrug sustained release oral dosage forms |
| WO2008060572A1 (en) | 2006-11-14 | 2008-05-22 | Xenoport, Inc. | Use of gabapentin and pregabalin prodrugs for treating tinnitus |
| CA2672044A1 (en) | 2006-12-08 | 2008-06-19 | Xenoport, Inc. | Use of prodrugs of gaba analogs for treating diseases |
-
2004
- 2004-10-14 CA CA2541752A patent/CA2541752C/en not_active Expired - Lifetime
- 2004-10-14 MX MXPA06004088A patent/MXPA06004088A/es active IP Right Grant
- 2004-10-14 KR KR1020067007286A patent/KR101096480B1/ko not_active Expired - Lifetime
- 2004-10-14 JP JP2006535673A patent/JP4308263B2/ja not_active Expired - Lifetime
- 2004-10-14 PT PT04795177T patent/PT1677767E/pt unknown
- 2004-10-14 EP EP04795177A patent/EP1677767B1/en not_active Expired - Lifetime
- 2004-10-14 DK DK04795177.7T patent/DK1677767T3/da active
- 2004-10-14 AT AT04795177T patent/ATE516801T1/de active
- 2004-10-14 ES ES04795177T patent/ES2368916T3/es not_active Expired - Lifetime
- 2004-10-14 SI SI200431753T patent/SI1677767T1/sl unknown
- 2004-10-14 SG SG200807649-9A patent/SG147437A1/en unknown
- 2004-10-14 PL PL04795177T patent/PL1677767T3/pl unknown
- 2004-10-14 BR BRPI0415288A patent/BRPI0415288B8/pt not_active IP Right Cessation
- 2004-10-14 US US10/966,507 patent/US8026279B2/en active Active
- 2004-10-14 RU RU2006116470/04A patent/RU2412162C2/ru not_active IP Right Cessation
- 2004-10-14 NZ NZ546381A patent/NZ546381A/en not_active IP Right Cessation
- 2004-10-14 WO PCT/US2004/033979 patent/WO2005037784A2/en not_active Ceased
- 2004-10-14 CN CN200480030148.4A patent/CN1867322B/zh not_active Expired - Fee Related
- 2004-10-14 AU AU2004282192A patent/AU2004282192B2/en not_active Ceased
-
2006
- 2006-03-27 IL IL174600A patent/IL174600A/en active IP Right Grant
- 2006-04-03 ZA ZA2006/02722A patent/ZA200602722B/en unknown
- 2006-05-11 NO NO20062112A patent/NO338275B1/no not_active IP Right Cessation
-
2008
- 2008-12-22 JP JP2008325914A patent/JP4913796B2/ja not_active Expired - Lifetime
-
2009
- 2009-08-26 US US12/548,200 patent/US20100056632A1/en not_active Abandoned
- 2009-12-08 IL IL202603A patent/IL202603A/en active IP Right Grant
-
2010
- 2010-10-04 US US12/897,567 patent/US20110021628A1/en not_active Abandoned
-
2011
- 2011-06-20 US US13/164,620 patent/US8686034B2/en not_active Expired - Fee Related
-
2014
- 2014-03-12 US US14/206,893 patent/US9150503B2/en not_active Expired - Lifetime
-
2015
- 2015-08-20 US US14/831,688 patent/US20150353483A1/en not_active Abandoned
-
2017
- 2017-03-13 US US15/457,191 patent/US20170183296A1/en not_active Abandoned
-
2019
- 2019-01-29 US US16/261,191 patent/US20190152900A1/en not_active Abandoned
-
2020
- 2020-01-13 US US16/741,113 patent/US20200283376A1/en not_active Abandoned
-
2021
- 2021-09-20 US US17/479,382 patent/US20220251031A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021536511A5 (enExample) | ||
| JP2010514806A5 (enExample) | ||
| ES2606752T3 (es) | Método para la preparación de (2S,3R)-N-(2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)benzofuran-2- carboxamida | |
| AU2017209250B2 (en) | Angiotensin II receptor antagonist metabolite and NEP inhibitor composite, and preparation method thereof | |
| JP2010514807A5 (enExample) | ||
| US20240165097A1 (en) | Pharmaceutical composition for the treatment of alzheimer's disease or dementia | |
| JP2011522827A5 (enExample) | ||
| ES2503465T3 (es) | Preparación y aplicaciones terapéuticas de (2S,3R)-N-2-((3-piridinil)metil)-1-azabiciclo[2.2.2]oct-3-il)-3,5-di-fluorobenzamida | |
| WO2011143872A1 (zh) | 一种(s)-4-羟基-2-氧代-1-吡咯烷乙酰胺晶型及其制备方法和用途 | |
| JP2011516417A5 (enExample) | ||
| CN103113405B (zh) | 苯磷硫胺多晶型体、制备方法及其应用 | |
| JP2009536176A5 (enExample) | ||
| TW201204724A (en) | Cis-tetrahydro-spiro(cyclohexane-1,1'-pyrido[3,4-b]indole)-4-amine derivatives | |
| EA201000384A1 (ru) | Новая полиморфная форма ротиготина и способ её получения | |
| JP2007508396A5 (enExample) | ||
| CN102351857A (zh) | 盐酸托烷司琼化合物 | |
| JP2021503480A5 (enExample) | ||
| JP2020536893A5 (enExample) | ||
| JP2022511869A (ja) | ムスカリンｍ１および／またはｍ４受容体アゴニストとしての二環式アザ化合物 | |
| JP2025521564A (ja) | Ｒ－ｍｄｍａ結晶形態 | |
| JP2012533559A5 (enExample) | ||
| JP2009518293A5 (enExample) | ||
| JP2024009114A (ja) | ミネラルコルチコイド受容体拮抗剤としての化合物の結晶形及びその調製方法 | |
| JP2009541455A5 (enExample) | ||
| TW200845977A (en) | Sub-type selective azabicycloalkane derivatives |